Table 2.

Subgroup analysis of progression‐free survival in the 20/27 mg/m² group

Carfilzomib, 20/27 mg/m2
Characteristic	Category	Event/total (%)	Median [95% CI] (mo)
Overall		32/40 (80.0)	5.1 [2.8, 13.6]
Sex	Male	15/18 (83.3)	7.0 [0.9, 17.1]
	Female	17/22 (77.3)	3.8 [2.8, 7.7]
Age (y) 1	<65	10/12 (83.3)	6.9 [0.9, 17.1]
	≥65	22/28 (78.6)	5.1 [2.6, 14.7]
Age (y) 2	<75	27/34 (79.4)	5.1 [2.8, 13.6]
	≥75	5/6 (83.3)	6.5 [1.3, 20.8]
ECOG performance status	0	16/23 (69.6)	5.8 [2.1, 22.8]
	1	16/17 (94.1)	4.5 [2.6, 13.6]
Stage (Durie‐Salmon)	I	7/7 (100.0)	5.1 [0.9, 26.3]
	II	9/10 (90.0)	2.8 [0.5, 22.8]
	III	14/18 (77.8)	3.7 [2.1, 13.6]
Stage (ISS)	1	10/12 (83.3)	3.9 [1.8, 22.8]
	2	10/14 (71.4)	5.1 [2.1, 13.6]
	3	7/9 (77.8)	6.9 [0.9, 26.2]
Stage (R‐ISS)	1	2/3 (66.7)	7.0 [0.9, 22.8]
	2	10/23 (43.5)	3.9 [2.8, 13.6]
	3	0/0	Not evaluable
No. of prior treatments	<5	14/16 (87.5)	2.9 [1.3, 7.0]
	≥5	18/24 (75.0)	6.9 [2.8, 22.8]
No. of prior bortezomib treatments	1	15/20 (75.0)	3.8 [2.6, 7.7]
	≥2	17/20 (85.0)	5.8 [1.8, 20.8]
Bortezomib at most recent treatment	Yes	13/13 (100.0)	3.9 [1.8, 7.7]
	No	19/27 (70.4)	6.9 [2.8, 17.1]
Prior lenalidomide treatment	Yes	26/33 (78.8)	5.8 [2.8, 14.7]
	No	6/7 (85.7)	2.9 [1.3, 20.8]
Prior thalidomide treatment	Yes	19/23 (82.6)	3.9 [2.1, 13.6]
	No	13/17 (76.5)	6.5 [1.8, 17.1]
Prior lenalidomide and thalidomide treatments	Yes	13/16 (81.3)	5.8 [1.8, 17.1]
	No	19/24 (79.2)	5.1 [2.6, 14.7]
Prior stem cell transplantation	Yes	16/17 (94.1)	3.4 [1.8, 13.6]
	No	16/23 (69.6)	5.8 [2.8, 17.1]
High‐risk cytogeneticsa	Yes	8/11 (72.7)	2.9 [0.5, 17.1]
	No	21/26 (80.8)	5.1 [2.1, 17.1]

CI, confidence interval; ECOG, European Cooperative Oncology Group; ISS, International Staging System; R‐ISS, revised ISS stage.

^aHigh‐risk cytogenetics were defined as positive for del(17p) in ≥20% of screened plasma cells, t(4;14), t(14;16), or hypodiploidy.